TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes
One of the hallmarks of cancer is its unlimited replicative potential that needs a compensatory mechanism for the consequential telomere erosion. Telomerase promoter (TERTp) mutations were recently reported as a novel mechanism for telomerase re-activation/expression in order to maintain telomere length. Pancreatic endocrine tumors (PETs) were so far recognized to rely mainly on the alternative lengthening of telomeres (ALT) mechanism. It was our objective to study if TERTp mutations were present in pancreatic endocrine tumors (PET) and could represent an alternative mechanism to ALT. TERTp mutations were detected in 7% of the cases studied and were mainly associated to patients harbouring hereditary syndromes. In vitro, using PET-derived cell lines and by luciferase reporter assay, these mutations confer a 2 to 4-fold increase in telomerase transcription activity. These novel alterations are able to recruit ETS transcription factor members, in particular GABP-α and ETV1, to the newly generated binding sites. We report for the first time TERTp mutations in PETs and PET-derived cell lines. Additionally, our data indicate that these mutations serve as an alternative mechanism and in an exclusive manner to ALT, in particular in patients with hereditary syndromes.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2016 |
---|---|
Erschienen: |
2016 |
Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
---|---|
Enthalten in: |
Scientific reports - 6(2016) vom: 14. Juli, Seite 29714 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Vinagre, João [VerfasserIn] |
---|
Links: |
---|
Themen: |
EC 2.7.7.49 |
---|
Anmerkungen: |
Date Completed 04.06.2018 Date Revised 13.11.2018 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/srep29714 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM262377934 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM262377934 | ||
003 | DE-627 | ||
005 | 20231226193019.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2016 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/srep29714 |2 doi | |
028 | 5 | 2 | |a pubmed24n0874.xml |
035 | |a (DE-627)NLM262377934 | ||
035 | |a (NLM)27411289 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Vinagre, João |e verfasserin |4 aut | |
245 | 1 | 0 | |a TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes |
264 | 1 | |c 2016 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 04.06.2018 | ||
500 | |a Date Revised 13.11.2018 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a One of the hallmarks of cancer is its unlimited replicative potential that needs a compensatory mechanism for the consequential telomere erosion. Telomerase promoter (TERTp) mutations were recently reported as a novel mechanism for telomerase re-activation/expression in order to maintain telomere length. Pancreatic endocrine tumors (PETs) were so far recognized to rely mainly on the alternative lengthening of telomeres (ALT) mechanism. It was our objective to study if TERTp mutations were present in pancreatic endocrine tumors (PET) and could represent an alternative mechanism to ALT. TERTp mutations were detected in 7% of the cases studied and were mainly associated to patients harbouring hereditary syndromes. In vitro, using PET-derived cell lines and by luciferase reporter assay, these mutations confer a 2 to 4-fold increase in telomerase transcription activity. These novel alterations are able to recruit ETS transcription factor members, in particular GABP-α and ETV1, to the newly generated binding sites. We report for the first time TERTp mutations in PETs and PET-derived cell lines. Additionally, our data indicate that these mutations serve as an alternative mechanism and in an exclusive manner to ALT, in particular in patients with hereditary syndromes | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a TERT protein, human |2 NLM | |
650 | 7 | |a EC 2.7.7.49 |2 NLM | |
650 | 7 | |a Telomerase |2 NLM | |
650 | 7 | |a EC 2.7.7.49 |2 NLM | |
700 | 1 | |a Nabais, Joana |e verfasserin |4 aut | |
700 | 1 | |a Pinheiro, Jorge |e verfasserin |4 aut | |
700 | 1 | |a Batista, Rui |e verfasserin |4 aut | |
700 | 1 | |a Oliveira, Rui Caetano |e verfasserin |4 aut | |
700 | 1 | |a Gonçalves, António Pedro |e verfasserin |4 aut | |
700 | 1 | |a Pestana, Ana |e verfasserin |4 aut | |
700 | 1 | |a Reis, Marta |e verfasserin |4 aut | |
700 | 1 | |a Mesquita, Bárbara |e verfasserin |4 aut | |
700 | 1 | |a Pinto, Vasco |e verfasserin |4 aut | |
700 | 1 | |a Lyra, Joana |e verfasserin |4 aut | |
700 | 1 | |a Cipriano, Maria Augusta |e verfasserin |4 aut | |
700 | 1 | |a Ferreira, Miguel Godinho |e verfasserin |4 aut | |
700 | 1 | |a Lopes, José Manuel |e verfasserin |4 aut | |
700 | 1 | |a Sobrinho-Simões, Manuel |e verfasserin |4 aut | |
700 | 1 | |a Soares, Paula |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 6(2016) vom: 14. Juli, Seite 29714 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
773 | 1 | 8 | |g volume:6 |g year:2016 |g day:14 |g month:07 |g pages:29714 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/srep29714 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 6 |j 2016 |b 14 |c 07 |h 29714 |